

Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?

Niels Willem Boone
Roelof Wouter Frederik van
Leeuwen

Maastricht University Medical Centre,
Department of Clinical Pharmacy
and Toxicology, Maastricht, The
Netherlands

Recently our hospital pharmacy, which serves an academic hospital with an internationally well-known department of ophthalmology, received a request for the aseptic preparation of an alteplase syringe solution for subretinal administration. Looking for dose rationale, our ophthalmology doctor came up with a concentration based on an article published by Arias and colleagues in *Clinical Ophthalmology* in 2010.¹ This article is on subretinal alteplase administration for hemorrhagic age-related macular degeneration. In the methods section, a concentration of 125 mg/mL alteplase was declared, which we found peculiar. This concentration cannot be acquired with the commercially available preparation (which has a maximum concentration of 2 mg/mL), and could lead to undesirable side effects. In the literature, it is stated that an alteplase dose should be in the range of 200 µg/mL.² Did the authors mean 125 µg/mL?

Disclosure

The authors declare no conflicts of interest in this work.

References

1. Arias L, Monés J. Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration. *Clin Ophthalmol.* 2010;18(4):67–72.
2. Treumer F, Klatt C, Roider J, Hillenkamp J. Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage. *Br J Ophthalmol.* 2010;94(1):48–53.

Correspondence: Niels Willem Boone
Maastricht University Medical Centre,
Department of Clinical Pharmacy and
Toxicology, P. Debyealaan 25, 6202 AZ,
Maastricht, The Netherlands
Tel +31 43 3876723
Fax +31 43 3874731
Email n.boone@mumc.nl

Clinical Ophthalmology is an international, peer-reviewed journal covering all subspecialties within ophthalmology. Key topics include: Optometry; Visual science; Pharmacology and drug therapy in eye diseases; Basic Sciences; Primary and Secondary eye care; Patient Safety and Quality of Care Improvements. This journal is indexed on

Submit your manuscript here: <http://www.dovepress.com/clinical-ophthalmology-journal>

PubMed Central and CAS, and is the official journal of The Society of Clinical Ophthalmology (SCO). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.